In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

There’s no data from a head-to-head trial directly comparing Eli Lilly ... drugs yet, but an observational study has found that Lilly’s tirzepatide seems to be better at achieving weight loss.

Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a weight-loss drug.

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...

But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...